Stock Research: BioLife Slutn

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

BioLife Slutn

NasdaqCM:BLFS US09062W2044
24
  • Value
    59
  • Growth
    53
  • Safety
    Safety
    24
  • Combined
    35
  • Sentiment
    46
  • 360° View
    360° View
    24
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

BioLife Solutions, Inc. develops and supplies cell processing tools and services for the cell and gene therapy (CGT) market. The company operates in the cell and gene therapy market, offering solutions for cell preservation and processing. Its products include CryoStor freeze media, Sexton cell processing product line, CellSeal cryogenic vials, and ThawSTAR thawing devices. In the last fiscal year, the company had a market cap of $1,000 million, profits of $54 million, and revenue of $82 million with 159 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 24 (better than 24% compared with alternatives), overall professional sentiment and financial characteristics for the stock BioLife Slutn are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for BioLife Slutn. The consolidated Growth Rank has a good rank of 53, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 53% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 59 which means that the company has a financing structure that is safer than 59% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 24 which means that the share price of BioLife Slutn is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 76% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 46, which means that professional investors are more pessimistic about the stock than for 54% of alternative investment opportunities. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
24 20 44 63
Growth
53 91 27 71
Safety
Safety
59 20 56 56
Sentiment
46 82 33 17
360° View
360° View
24 71 81 57
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
79 84 61 23
Opinions Change
50 50 50 50
Pro Holdings
n/a 63 32 75
Market Pulse
47 40 36 16
Sentiment
46 82 33 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
24 20 44 63
Growth
53 91 27 71
Safety Safety
59 20 56 56
Combined
35 33 72 72
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
58 58 58 6
Price vs. Earnings (P/E)
7 11 38 62
Price vs. Book (P/B)
55 40 58 79
Dividend Yield
1 1 1 1
Value
24 20 44 63
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
69 4 10 71
Profit Growth
60 90 90 9
Capital Growth
7 95 9 91
Stock Returns
59 87 47 53
Growth
53 91 27 71
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
75 60 53 62
Refinancing
43 18 39 31
Liquidity
23 14 28 28
Safety Safety
59 20 56 56

Similar Stocks

Discover high‑ranked alternatives to BioLife Slutn and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Intuit

NasdaqGS:INTU
Country: USA
Industry: Application Software
Size: X-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.